文献速递膀胱癌与上尿路尿路上皮癌

六氨基乙酰丙酸蓝光柔性膀胱镜在非肌层浸润性膀胱癌中的前瞻性评估

Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2020-08-06

该前瞻性队列研究纳入190例非肌层浸润性膀胱癌患者,共进行322例次门诊蓝光柔性膀胱镜(BLFC)检查。结果显示,白光膀胱镜(WLC)正常而BLFC异常者占8%,其中活检癌症检出率87%;WLC与BLFC均阳性者占25.8%,其中33%发现额外肿瘤。结论认为BLFC有助于发现WLC漏诊的癌症并改善门诊活检效果。

要点

  • WLC正常而BLFC异常者占8%,活检癌症检出率87%。
  • WLC与BLFC均阳性者中33%发现额外肿瘤。
  • BLFC可改善门诊活检性能,但成本效果与复发影响待研究。

核心结论

  • 在临床实践中纳入BLFC可能有助于发现WLC正常的癌症病例。
  • BLFC在WLC和BLFC均阳性的患者中检测到33%的额外癌症,可改善监测和门诊活检性能。
  • 需要进一步研究确定成本效果和对复发率的影响。

研究设计与样本

  • 前瞻性队列研究,连续纳入接受门诊BLFC监测的非肌层浸润性膀胱癌患者。
  • 共对190例患者进行了322例次检查。
  • 平均年龄71岁,83%为男性。

主要发现

  • BLFC前最高分期为Ta、原位癌(CIS)、T1和T2的比例分别为45.3%、18.4%、30%和2%。
  • BLFC前低级别、高级别和CIS的比例分别为16.8%、60.5%和16.8%。
  • WLC和BLFC均正常者173例次(53.7%)。
  • WLC正常而BLFC异常者26例次(8%),其中15例接受门诊活检,13例(87%)检出癌症(6例CIS,4例高级别Ta,3例低级别Ta)。
  • WLC和BLFC均阳性者83例次(25.8%),其中33%发现额外肿瘤;接受门诊活检的27例中75%检出癌症(19例低级别Ta,6例高级别Ta,2例CIS)。

临床怎么用

  • 对于NMIBC监测,可考虑采用BLFC以提高WLC正常病例的癌症检出率。
  • BLFC有助于发现额外肿瘤,可能改善门诊活检的准确性。

局限性

  • 需要进一步研究确定成本效果和对复发率的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the utility of blue-light flexible cystoscopy (BLFC) for surveillance of non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Prospective cohort of consecutive patients who underwent office-based BLFC for NMIBC. Clinical information was collected including cystoscopic findings and pathological data. RESULTS: A total of 322 cases were performed on 190 patients. The mean age was 71 years and 83% were men. The highest stage prior to BLFC was Ta, carcinoma in situ (CIS), T1, and T2 in 45.3%, 18.4%, 30% and 2%, respectively. Prior to BLFC, 16.8%, 60.5%, and 16.8% were low grade (LG), high grade (HG), and CIS, respectively. Intravesical bacille Calmette-Guérin and intravesical chemotherapy were used in 54.2% and 18.4%, respectively. White-light cystoscopy (WLC) and BLFC were both normal in 173 (53.7%) of cases. WLC was normal and BLFC was abnormal in 26 (8%) cases. Of these, 15 had office-based biopsy and cancer was detected in 13 (87%; six CIS, four HG Ta, three LG Ta). Both WLC and BLFC were positive in 83 (25.8%) cases and 33% had additional tumours found. Cancer was found in 27 (75%) of WLC+/BLFC+ who underwent office-based biopsy including 19 LG Ta, six HG Ta, and two CIS. CONCLUSIONS: Incorporation of BLFC in clinical practice has potential advantages of finding cancer in cases with normal WLC. BLFC detected additional cancers in 33% of patients with positive WLC and BLFC, which can improve surveillance and performance of office-based biopsy. Further research is needed to determine cost-effectiveness and impact on recurrence rates.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lotan Y, Chaplin I, Ahmadi H, et al. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. BJU Int. 2020. PMID: 32648957. doi:10.1111/bju.15166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。